Free Cash Flow for Regeneron Pharmaceuticals (REGN)
Free Cash Flow for Regeneron Pharmaceuticals (REGN): headline value $4.08B · YoY +11.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingFree Cash FlowSwitch metric
Latest period
$4.08B
YoY change
+11.3%
5Y CAGR
+15.3%
Peak year (2021)
$6.53B
Latest annual
$4.08B
Free Cash Flow history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Free Cash Flow history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| Fiscal year | Period ended | Reported | Free Cash Flow | YoY |
|---|---|---|---|---|
| 2025 | $4.08B | +11.3% | ||
| 2024 | $3.66B | -0.1% | ||
| 2023 | $3.67B | -17.1% | ||
| 2022 | $4.42B | -32.2% | ||
| 2021 | $6.53B | +225.9% | ||
| 2020 | $2.00B | +0.2% | ||
| 2019 | $2.00B | +10.4% | ||
| 2018 | $1.81B | +75.2% | ||
| 2017 | $1.03B | +6.2% | ||
| 2016 | $974.00M | +49.2% | ||
| 2015 | $652.85M | +55.7% | ||
| 2014 | $419.43M | -3.0% | ||
| 2013 | $432.27M | -448.7% | ||
| 2012 | -$123.95M | -37.7% | ||
| 2011 | -$198.90M | +5846.2% | ||
| 2010 | -$3.35M | -98.0% | ||
| 2009 | -$169.55M | +36.8% | ||
| 2008 | -$123.94M | -1488.6% | ||
| 2007 | $8.93M | -56.0% | ||
| 2006 | $20.26M | -157.5% | ||
| 2005 | -$35.26M | +52.8% | ||
| 2004 | -$23.08M | -35.5% | ||
| 2003 | -$35.79M | -75.3% | ||
| 2002 | -$144.89M | +121.1% | ||
| 2001 | -$65.54M | +90.5% | ||
| 2000 | -$34.41M | +76.4% | ||
| 1999 | -$19.50M | +47.7% | ||
| 1998 | -$13.20M | +61.0% | ||
| 1997 | -$8.20M | -71.6% | ||
| 1996 | -$28.90M | +34.4% | ||
| 1995 | -$21.50M | -21.5% | ||
| 1994 | -$27.40M | -32.0% | ||
| 1993 | -$40.30M | +108.8% | ||
| 1992 | -$19.30M | +147.4% | ||
| 1991 | -$7.80M | — |
Free Cash Flow values are taken from Regeneron Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Regeneron Pharmaceuticals (REGN) most recent annual free cash flow stands at $4.08B (2025) – grew 11.3% year-over-year.
Regeneron Pharmaceuticals free cash flow has recorded the values shown across consecutive periods, with a +15.3% compound annual growth rate over 2020–2025 (5 years).
Regeneron Pharmaceuticals free cash flow plunged from $6.53B in 2021 to $4.08B in 2025, a 37.5% drawdown.
$6.53B stands as the all-time-high annual free cash flow, posted in 2021, against a low of -$198.90M during 2011.
Within Healthcare, Regeneron Pharmaceuticals (REGN) ranks 9th among 8 peers we track. The peer median for free cash flow is $14.22B.
Regeneron Pharmaceuticals Free Cash Flow by Year
Regeneron Pharmaceuticals Free Cash Flow 2025: $4.08B
Regeneron Pharmaceuticals free cash flow in 2025 was $4.08B, grew 11.3% from 2024.
Regeneron Pharmaceuticals Free Cash Flow 2024: $3.66B
Regeneron Pharmaceuticals free cash flow in 2024 was $3.66B, edged down 0.1% below 2023.
Regeneron Pharmaceuticals Free Cash Flow 2023: $3.67B
Regeneron Pharmaceuticals free cash flow in 2023 was $3.67B, declined 17.1% below 2022.
Regeneron Pharmaceuticals Free Cash Flow 2022: $4.42B
Regeneron Pharmaceuticals free cash flow in 2022 was $4.42B, plunged 32.2% below 2021.
Regeneron Pharmaceuticals Free Cash Flow 2021: $6.53B
Regeneron Pharmaceuticals free cash flow in 2021 was $6.53B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Free Cash Flow
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest free cash flow.
| Company | Free Cash Flow | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $28.99B | Healthcare |
| Johnson & Johnson (JNJ) | $19.70B | Healthcare |
| AbbVie Inc. (ABBV) | $17.82B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $16.07B | Healthcare |
| Merck & Co., Inc. (MRK) | $12.36B | Healthcare |
| AstraZeneca PLC (AZN) | $11.77B | Healthcare |
| Eli Lilly and Company (LLY) | $8.97B | Healthcare |
| Amgen Inc. (AMGN) | $8.10B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's free cash flow?
Latest reported free cash flow for Regeneron Pharmaceuticals (REGN) is $4.08B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals free cash flow changed year-over-year?
Regeneron Pharmaceuticals (REGN) free cash flow changed +11.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals free cash flow?
Regeneron Pharmaceuticals (REGN) free cash flow compound annual growth rate is +15.3% over the most recent 5 years available.
When did Regeneron Pharmaceuticals free cash flow hit its highest annual value?
Regeneron Pharmaceuticals free cash flow reached its highest annual value of $6.53B in 2021.
What was Regeneron Pharmaceuticals free cash flow in 2024?
Regeneron Pharmaceuticals (REGN) free cash flow in 2024 was $3.66B.
What was Regeneron Pharmaceuticals free cash flow in 2025?
Regeneron Pharmaceuticals (REGN) free cash flow in 2025 was $4.08B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.